


# بسم الله الرحمن الرحيم



**HOSSAM MAGHRABY**



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكرو فيلم



HOSSAM MAGHRABY



# جامعة عين شمس

## التوثيق الإلكتروني والميكروفيلم

### قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
على هذه الأقراص المدمجة قد أعدت دون أية تغيرات




## يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

**HOSSAM MAGHRABY**



# بعض الوثائق الأصلية تالفة



HOSSAM MAGHRABY





بالرسالة صفحات

لم ترد بالأصل



HOSSAM MAGHRABY

# ***MDR1 Gene Expression in Acute Leukemia***

**B1555N**

*Thesis*

*Submitted in Partial Fulfillment of the M.Sc. Degree*

*In*

***Clinical and Chemical Pathology***

*By*

***Manal Assem Abdel Sattar***

*M.B., B.Ch. (Cairo University)*

*Supervisors*

*Professor Doctor*

***Taghrid Mohamed Gaafar***

*Professor of Clinical Pathology*

*Faculty of Medicine , Cairo University*

*Doctor*

***Dina Ahmad Yassin***

*Assistant professor of Clinical Pathology*


*National Cancer Institute*

*Cairo University*

*Faculty of Medicine*

*Cairo University*

*2002*









## ***Acknowledgment***

*Before all and above all ... Thanks to **ALLAH** for every thing, and to my **Parents**.*

*I would like to express my deep gratitude and appreciation to **Prof. Dr. Taghrid Gaafar**, Professor of microbiology and Immunology, Faculty of Medicine Cairo University, for her valuable guidance, instructive supervision and sincere encouragement.*


*I am greatly thankful to **Dr. Dina Yassin** Assistant Professor of microbiology, and Immunology, NCI. Cairo University for her kind help through the whole work and her valuable advice.*

*My deepest gratitude to **Proff. Dr Azza Kamel** for her precious pieces of advice through all the study.*


*Many thanks to **Dr. Nelly** and **Dr. Salah Fahmy** for their precious statistical analysis, and many thanks to **Dr. Magdah Fahmy**.*

*I would like to thank **Dr. Heba Abd El Razik** for her sincere help in revising and ending the study.*

*Many thanks to Prof. **Dr Nayera Hamdi**, **Dr. Nahla El Sharkawy**, Prof. **Dr. Heba Shaker**, **Dr Ghada Mossallam**, **Dr. Heba Mossa** and **Dr. Khaled Shaaban**, the staff member of the Bone marrow transplantation unit. They were all supportive and encouraging. Finally, I would like to thank all the staff members of the Microbiology and Immunology Department, NCI, Cairo University for their excellent support and cooperation.*







## Abstract

Therapeutic resistance has been associated with rapid drug efflux mediated by the multidrug resistance gene (MDR1; encoding P-glycoprotein). Detection of MDR1 expression by monoclonal antibody (JSB1) in 94 acute leukemia patients by using immunocytochemistry. The results were correlated with different clinical risk indicator and hematological data, as well as remission rate. MDR1 was not found to be linked to any of the prognostic features in Precursor B-ALL cases; no correlation with absolute total leucocytic count, hemoglobin concentration, bone marrow blast percent, clinical presentation, or sex. Many author proved that MDR1 increase in 2<sup>nd</sup> and 3<sup>rd</sup> relapse of B- ALL but not in 1<sup>st</sup> relapse. On the contrary, MDR1 expression was significantly higher in relapsed T-ALL than newly diagnosed ( $p=0.02$ ). There was significant association with MDR1 expression and generalized lymphadenopathy ( $p=0.01$ ), and male patients ( $p=0.01$ ). In this study MDR1 in AML is significantly higher in relapse than in new ( $p=0.01$ ) cases. It is associated with bad prognostic features such as, splenomegally ( $p=0.05$ ), unfavorable age group ( $p=0.01$ ), and male ( $p=0.02$ ) while, average correlation was encountered with total leucocytic count. Complete remission in both ALL and AML group was not found related to MDR1. Only in ALL the new MDR1+ group in relation to the relapsed MDR1+ were ( $p=0.02$ ).

Key words; MDR1, ALL, AML.

## **CONTENTS**

<b>Introduction and aim of work</b>	1
<b>Review of Literature</b>	
<b>Acute leukemia</b>	3
ALL	4
AML	7
Classification	9
Cytogenetics	17
Recent classification of acute leukemia	19
Prognostic features	21
<b>Drug resistance</b>	24
Resistance to multiple drugs	31
Classical MDR1	32
Atypical MDR1	44
MRP	44
GST	47
MDR3	49
LRP	50
<b>MDR1 methods of detection</b>	53



Clonogenic assay	54
Immunocytochemistry	55
Flow cytometry	56
Molecular technique	61
<b>MDR1 modulation</b>	63
Modulating drugs	67
Killing MDR1 cells	75
Exploiting MDR1 cells	76
<b>MDR1 in acute leukemia</b>	77
MDR1 in AML	77
MDR1 in ALL	82
<b>Materials and methods</b>	86
<b>Results</b>	94
<b>Discussion</b>	109
<b>Summary</b>	121
<b>References</b>	123
<b>Appendix</b>	
<b>Arabic summary</b>	